Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Thoracic malignancies 1

1977 - The clinical impact of PD-L1 protein expression in non-small cell lung carcinoma (395O)


17 Nov 2017


Thoracic malignancies 1


Translational Research;  Non-Small Cell Lung Cancer


Naoki Yanagawa


Annals of Oncology (2017) 28 (suppl_10): x119-x121. 10.1093/annonc/mdx669


N. Yanagawa1, S. Shiono2, S. Ogata1

Author affiliations

  • 1 Diagnostic Pathology, Yamagata Prefectural Central Hospital, 990-2292 - Yamagata/JP
  • 2 Thoracic Surgery, Yamagata Prefectural Central Hospital, 990-2292 - Yamagata/JP


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1977


Programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) are important targets of immunotherapy and its expression has been closely correlated with response and survival benefit from anti-PD-1/PD-L1 immune checkpoint inhibitor therapies in advanced non-small cell lung carcinoma (NSCLC). But it is still unclear whether PD-L1 is prognostic. The aim of this study is to examine the proportion of PD-L1 protein expression in NSCLC and investigate the correlation with clinicopathological backgrounds including patient outcome.


A total of 899 NSCLC were examined. The male:female ratio was 550:349; the age range was between 32 and 89 years of age and the mean age was 68.9 years. Adenocarcinoma: Squamous cell carcinoma: Others’ ratio was 647:209:43 in histopathology. The follow up duration was from 0.4 months to 168.7 months and the mean duration was 62.2 months. PD-L1 expression was analyzed using immunohistochemistry (VENTANA; clone SP263) in stages I-IV NSCLC using tissue microarray. The PD-L1 staining percentage in tumor cells were scored as follows: 0, 0%; 1, 1-24%; 2, 25-49%; 3, ≥50%. The score of PD-L1 staining was correlated with clinicopathological backgrounds, molecular features and patient outcome.


The score of PD-L1 staining was as follows: 0, 739/899 (82.2%); 1, 47/899 (5.2%); 2, 26/899 (2.9%); 3, 87/899 (9.7%). PD-L1 expression was associated with sex, smoking history, histology, tumor size, stage, pleural invasion, p53 protein expression, MIB-1 labeling index and EGFR mutation. We arranged the value of cut offs at ≥ 1%, ≥25%, ≥50% and investigated the correlation with patient outcome. In adenocarcinoma, the patients with any positive staining of PD-L1 (≥1%) had a trend of worse 5-year overall survival rate than those with negative staining of PD-L1 (73.5% vs. 79%, p = 0.096). In squamous cell carcinoma, PD-L1 expression was not prognostic with these cut offs. In multivariate analysis, PD-L1 expresssion was not independent prognostic factor in adenocarcinoma.


Our study shows PD-L1 protein expression is not a prognostic factor in NSCLC.

Clinical trial identification

Legal entity responsible for the study

Naoki Yanagawa




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.